[go: up one dir, main page]

CY1110320T1 - Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide) - Google Patents

Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)

Info

Publication number
CY1110320T1
CY1110320T1 CY20091100623T CY091100623T CY1110320T1 CY 1110320 T1 CY1110320 T1 CY 1110320T1 CY 20091100623 T CY20091100623 T CY 20091100623T CY 091100623 T CY091100623 T CY 091100623T CY 1110320 T1 CY1110320 T1 CY 1110320T1
Authority
CY
Cyprus
Prior art keywords
preparation
nateglinide
hydrophilic
contents
sugars
Prior art date
Application number
CY20091100623T
Other languages
English (en)
Inventor
Nobutaka Ninomiya
Chisato Makino
Akira Yabuki
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of CY1110320T1 publication Critical patent/CY1110320T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Προσφέρεται υδρόφιλον φαρμακευτικóν παρασκεύασμα περιέχον-νατεγλινίδη (nateglinide) το οποίον περιλαμβάνει κρυστάλλους νατεγλινίδης Β-τύπου ως δραστικόν συστατικό της γωνίας επαφής της επιφανείας του ρηθέντος παρασκευάσματος προς το ύδωρ καθισταμένης 111 μοίρες ή ολιγώτερον δι'ενσωματώσεως εις το ρηθέν παρασκεύασμα τουλάχιστον μιας υδρoφíλου ουσίας εκλεγόμενης εκ των ομάδων των συνισταμένων εξ υδρoφíλων πολυμερών, επιφανειακώς δρωσών ουσιών, σακχάρων σάκχαρο-αλκοολών και αλάτων. Το παρασκεύασμα αυτό, είναι παρασκεύασμα, το οποίο έχει ιδιότητες επαρκούς αμέσου απελευθερώσεως και μεγάλης διαλύσεως, και ημπορεί να παρασκευασθή εύκολα.
CY20091100623T 2000-10-24 2009-06-11 Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide) CY1110320T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324374 2000-10-24
EP01976818A EP1334721B1 (en) 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations

Publications (1)

Publication Number Publication Date
CY1110320T1 true CY1110320T1 (el) 2015-01-14

Family

ID=18801919

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100623T CY1110320T1 (el) 2000-10-24 2009-06-11 Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)

Country Status (19)

Country Link
US (1) US20040029968A1 (el)
EP (1) EP1334721B1 (el)
JP (3) JPWO2002040010A1 (el)
KR (1) KR100829410B1 (el)
CN (1) CN100531730C (el)
AT (1) ATE429217T1 (el)
AU (1) AU2001296000A1 (el)
BR (1) BR0114897A (el)
CA (1) CA2426764C (el)
CY (1) CY1110320T1 (el)
DE (1) DE60138476D1 (el)
DK (1) DK1334721T3 (el)
ES (1) ES2321911T3 (el)
MX (1) MXPA03003686A (el)
PT (1) PT1334721E (el)
RU (1) RU2283104C2 (el)
SI (1) SI1334721T1 (el)
TW (1) TWI289461B (el)
WO (1) WO2002040010A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616561B1 (en) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2005094812A1 (ja) * 2004-04-01 2005-10-13 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2009038770A2 (en) * 2007-09-20 2009-03-26 University Of Massachusetts Cvip Detoxified recombinant botulinum neurotoxin
WO2013066278A1 (en) * 2011-11-03 2013-05-10 Mahmut Bilgic A process for production of pharmaceutical formulations comprising nateglinide
WO2013115739A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Production method for formulations comprising comprising nateglinide and lipoic acid
US20230201185A1 (en) * 2020-03-27 2023-06-29 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066532B2 (ja) * 1983-09-29 1994-01-26 日産化学工業株式会社 親水性コロイドにより変性したワックス性微粉末
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ATE149483T1 (de) * 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
JPH0696517B2 (ja) 1993-03-17 1994-11-30 日産化学工業株式会社 変性したワックス性微粉末で被覆された薬剤及びその製造法
JP2994956B2 (ja) 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3591801B2 (ja) * 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
JP2000178183A (ja) * 1998-12-17 2000-06-27 Lion Corp 固形製剤及びその製造方法
JP2000290171A (ja) * 1999-04-06 2000-10-17 Eisai Co Ltd 崩壊のはやい錠剤又はその製造方法
EP1616561B1 (en) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
KR100819358B1 (ko) * 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
PT1334964E (pt) * 2000-10-24 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida na forma b
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
ATE429217T1 (de) 2009-05-15
JP5673972B2 (ja) 2015-02-18
TWI289461B (en) 2007-11-11
KR20030042028A (ko) 2003-05-27
US20040029968A1 (en) 2004-02-12
JP5278708B2 (ja) 2013-09-04
RU2283104C2 (ru) 2006-09-10
PT1334721E (pt) 2009-06-01
BR0114897A (pt) 2003-08-12
EP1334721A1 (en) 2003-08-13
ES2321911T3 (es) 2009-06-15
CA2426764A1 (en) 2003-04-23
EP1334721A4 (en) 2005-11-02
SI1334721T1 (sl) 2009-08-31
JPWO2002040010A1 (ja) 2004-06-03
DK1334721T3 (da) 2009-07-06
DE60138476D1 (de) 2009-06-04
EP1334721B1 (en) 2009-04-22
CN100531730C (zh) 2009-08-26
WO2002040010A1 (fr) 2002-05-23
AU2001296000A1 (en) 2002-05-27
CN1482904A (zh) 2004-03-17
KR100829410B1 (ko) 2008-05-15
JP2010095551A (ja) 2010-04-30
JP2013064018A (ja) 2013-04-11
MXPA03003686A (es) 2004-01-26
CA2426764C (en) 2010-04-20

Similar Documents

Publication Publication Date Title
CY1110320T1 (el) Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
CA2309836A1 (en) Drug delivery systems utilizing liquid crystal structures
AR029716A1 (es) Productos dermatologicos en forma de hoja
WO2002011716A3 (en) Liquid formulation of metformin
TNSN03138A1 (en) PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT
BE899635A (fr) Compositions pharmaceutiques.
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
ES2075249T3 (es) Dispositivo adhesivo para la administracion transdermica de un agente activo.
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
ES2193726T3 (es) Formulaciones de aerosol medicinales.
ES2075061T3 (es) Composicion farmaceutica a base de una resina de intercambio ionico.
PL346714A1 (en) Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications
RU2003111949A (ru) Гидрофильный фармацевтический препарат, содержащий натеглинид
ATE210444T1 (de) Antihyperglykämisch wirksame arzneimittel
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
DE69617868D1 (de) Geschmacksmaskierte wässrige Lösungen enthaltend Ibuprofen und Menthol
AR025393A1 (es) Pildoras de desintegracion rapida basadas en quitosan
WO2004037226B1 (en) Pharmaceutical compositions containing venlafaxine
RU2000113775A (ru) Препарат для профилактики и лечения эндометрита
RU93048844A (ru) Средство "бентокомплекс" для профилактики и лечения эндометрита у коров
RU98105696A (ru) Средство для лечения и профилактики болезней полости рта
WO2025006671A3 (en) Oral care compositions comprising hops beta acids